Fierce Pharma June 30, 2022
Ben Adams

Most pharma drug launches over the past three years have “underperformed expectations” and show the need for a major change in thinking about how to sell and market new meds.

That’s according to a new report, “Empowering the Next-Generation Launch Model,” out by life science consultants Trinity Life Sciences, which shows 62% of drug launches between September 2019 and December 2021 “underperformed expectations.”

These launches have not kept up with the “dramatic shifts” in scientific innovation over the last decade, the report found.

“No longer can life sciences companies rely on the traditional sales and marketing approaches to launching new products,” Leslie Orne, president and chief commercial officer of Trinity Life Sciences, said in a statement....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma, Pharma / Biotech, Survey / Study, Trends
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
Pharmacies Should Adopt Proactive Health, Wellness to Help Patients
Advancing Healthcare Solutions: Harnessing Collaborative Business Models for Oncology
AI Identifies New Potential Treatments For Parkinson’s Disease

Share This Article